Onychomycosis of Toenail

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Axiom
AxiomCA - San Francisco
1 program
1
2.4% Topical TerbinafinePhase 21 trial
Active Trials
NCT07382427Not Yet RecruitingEst. Feb 2028
VP
Vanda PharmaceuticalsWASHINGTON, DC
1 program
1
Trichostatin APhase 21 trial
Active Trials
NCT07065773Active Not Recruiting50Est. Sep 2026

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
Axiom2.4% Topical Terbinafine
Vanda PharmaceuticalsTrichostatin A

Clinical Trials (2)

Total enrollment: 50 patients across 2 trials

NCT07382427Axiom2.4% Topical Terbinafine

A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenails

Start: Mar 2026Est. completion: Feb 2028
Phase 2Not Yet Recruiting

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

Start: May 2025Est. completion: Sep 202650 patients
Phase 2Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space